Saturday 17 October 2026
Export LBRX’s income statement to Excel — free account
LB Pharmaceuticals Inc
LBRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 87.4% and free cash flow fell 579.0%, each against the same quarter a year earlier.
36.74
0.05
+0.14%
Follow LBRX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 13.36 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 23.15 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 16 | 27 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | — | (63) | (25) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | — | (63) | (25) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | — | (176.26) | (3.13) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (148.19) | (4.38) | |||||
| Capex | — | — | — | — | — | — | — | — | (2.15) | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (150.34) | (4.38) | |||||
| Book value | — | — | — | — | — | — | — | — | 55.04 | 37.45 | |||||
| Shares, m | — | — | — | — | — | — | — | — | 0 | 8 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (53) | (35) | ||||
| Capex | — | — | — | — | — | — | — | — | (1) | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (54) | (35) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 21 | 301 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | (28) | (295) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 20 | 301 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (14.55) | ||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (311.67) | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (24.38) | |||||
Negative figures in brackets.
Charts ten years each
LB Pharmaceuticals Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SNDX Syndax Pharmaceuticals, Inc. | $1.2B | — (loss-making) | — (loss-making) | +91.76% (above 0%: growing) | n/m | +65.47% (above 0%: growing) | 95.59% | (54.95%) | Compare |
| TSHA Taysha Gene Therapies, Inc. | $1.2B | — (loss-making) | — (loss-making) | +206.77% (above 0%: growing) | n/m | −100.28% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LBRX LB Pharmaceuticals Inc | $1.2B | — (loss-making) | — | — | n/m | −579.03% (below 0%: shrinking) | — | 0.00% | |
| BCAX Bicara Therapeutics Inc. | $1.2B | — (loss-making) | — | — | n/m | −72.95% (below 0%: shrinking) | — | 0.00% | Compare |
| DMRA Galecto, Inc. | $1.2B | — (loss-making) | — | — | n/m | −877.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VOR Vor Biopharma Inc. | $1.1B | — (loss-making) | — | — | n/m | −47.59% (below 0%: shrinking) | 0.00% | — | Compare |
| NBTX Nanobiotix S.A. - Sponsored ADR | $1.1B | — (loss-making) | — | −71.69% (below 0%: shrinking) | n/m | −177.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| REPL Replimune Group, Inc. | $1.1B | — (loss-making) | — | — | n/m | +5.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $1.2B | — | — | +91.76% | — | −60.27% | 0.00% | 0.00% |
LB Pharmaceuticals Inc (LBRX) key facts
- LB Pharmaceuticals Inc (LBRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, LBRX traded at $36.74, a market capitalization of $1.2 billion.
- Return on equity was −24.4% and debt-to-equity 0.00.